Design and in silico screening of inhibitors of the cholera toxin

Expert Opinion on Drug Discovery

Volumn 4, Issue 9, 2009, Pages 923-938

  Zhang, Guangtao ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cholera toxin; GM1; Inhibitor; Multivalency; Substrate analogue; Sugar mimic; Transition state analogue; Virtual screening

Indexed keywords

2 (3 CARBAMOYLBENZYL) 4 HYDROXY 5 (PHOSPHONOOXYMETHYL)ISOXAZOLIDIN 2 IUM; ANTITOXIN; CHOLERA TOXIN; CHOLERA TOXIN A SUBUNIT; CHOLERA TOXIN B SUBUNIT; CHOLERA TOXIN INHIBITOR; DENDRIMER; DIETHYLAMINO(BENZYLIDINEAMINO)GUANIDINE; UNCLASSIFIED DRUG;

ADENOSINE DIPHOSPHATE RIBOSYLATION; CATALYSIS; COMPUTER MODEL; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOXIN STRUCTURE; TOXIN SYNTHESIS;

EID: 70249106100     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440903186118     Document Type: Review

References (111)

1. In Cholera. WHO Cholera Fact Sheet November, 2008
2. World Health Organization. Wkly Epidemiol Rec 2006;81:297
3. In World Health Organization. Disease outbreak news February 20, 2009
4. In Cholera cases and deaths reported to WHO. WHO Weekly 2002
5. Pulungsih SP, Punjabi NH, Rafli K, et al. Standard WHO-ORS versus reducedosmolarity ORS in the management of cholera patients. J Health Popul Nutr 2006;24:107-112 (Pubitemid 43984545)
6. Sack DA, Sack RB, Chaignat CL. Getting serious about cholera. N Engl J Med 2006;355:649-651
7. De SN. Enterotoxicity of bacteria-free culture-filtrate of Vibrio cholerae. Nature 1959;183:1533-1534
8. Dutta NK, Panse MV, Kulkarni DR. Role of cholera toxin in experimental cholera. J Bacteriol 1959;78:594-595
9. Finkelstein RA, Norris HT, Dutta NK. Pathogenesis experimental cholera in infant rabbits. J Infect Dis 1964;114:203-216
10. Lencer WI. Retrograde transport of cholera toxin into the ER of the host cells. Int. J Med Microbiol 1994;293:491-494
11. Robinshaw JD, Russel DW, Harris BA, et al. Deduced primary structure of the alpha subunit of the GTP-binding stimulatory protein of adenylate cyclase. Proc Natl Acad Sci USA 1986;83:1251-1255
12. Merrit EA, Hol WG. AB5 toxins. Curr Opin Struct Biol 1995;5:165-171
13. Sixma TK, Pronk SE, Kalk KH, et al. Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli. Nature 1991;351:371-377
14. Fraser ME, Chernaia MM, Kozlov YV, James MN. Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 A resolution. Nat Struct Biol 1994;1:59-64
15. Yang J, Mou J, Shao Z. Structure and stability of pertussis toxin studied by in situ atomic force microscopy. FEBS Lett 1994;338:89-92 (Pubitemid 24047788)
16. Stein PE, Boodhoo A, Tyrrell GJ, et al. Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli. Nature 1992;355:748-750
17. Fan E, Merritt EA, Verlinde CLMJ, Hol WGJ. AB5 toxins: structures and inhibitor design. Curr Opin Struct Biol 2000;10:680-686 (Pubitemid 32061483)
18. Chong DC, Paton JC, Thorpe CM, Paton AW. Clathrin-dependent trafficking of subtilase cytotoxin, a novel AB5 toxin that targets the endoplasmic reticulum chaperone BiP. Cell Microbiol 2008;10:795-806
19. Pugsley AP. The complete general secretory pathway in gram-negative bacteria. Microbiol Rev 1993;57:50-108 (Pubitemid 23078438)
20. Robien MA, Krumm BE, Sandkvist M, Hol WG. Crystal structure of the extracellular protein secretion NTPase EpsE of Vibrio cholerae. J Mol Biol 2003;333:657-674 (Pubitemid 37222412)
21. Kahn RA, Fu H, Roy CR. Cellular hijacking: a common strategy for microbial infection. Trends Biochem Sci 2002;27:308-314 (Pubitemid 34628671)
22. Majoul IV, Bastiaens PI, Soling HD. Transport of an external Lys-Asp-Glu-Leu (KDEL) protein from the plasma membrane to the endoplasmic reticulum: studies with cholera toxin in Vero cells. J Cell Biol 1996;133:777-789
23. Lencer WI, Constable C, Moe S, et al. Targeting of cholera toxin and Escherichia coli heat labile toxin in polarized epithelia: role of COOH-terminal KDEL. J Cell Biol 1995;131:951-962
24. Tsai B, Rodighiero C, Lencer WI, Rapoport TA. Protein disulfide dsomerase acts as a redox-dependent chaperone to unfold cholera toxin. Cell 2001;104:937-948 (Pubitemid 32289285)
25. Bastiaens PI, Majoul IV, Verveer PJ, et al. Imaging the intracellular trafficking and state of the AB5 quaternary structure of cholera toxin. EMBO J 1996;15:4246-4253
26. Schmitz A, Herrgen H, Winkeler A, Herzog V. Cholera toxin is exported from microsomes by the Sec61p complex. J Cell Biol 2000;148:1203-1212 (Pubitemid 30688129)
27. Teter K, Holmes RK, Schmitz A, et al. Inhibition of endoplasmic reticulum-associated degradation in CHO cells resistant to cholera toxin, Pseudomonas aeruginosa exotoxin A, and ricin. Cholera toxin is exported from microsomes by the Sec61p complex. Infect Immun 2002;70:6172-6179
28. Tsai B, Rapoport TA. Unfolded cholera toxin is transferred to the ER membrane and released from protein disulfide isomerase upon oxidation by Ero1. J Cell Biol 2002;159:207-216 (Pubitemid 35283390)
29. Salmond RJ, Luross JA, Williams NA. Immune modulation by the cholera-like enterotoxins. Expert Rev Mol Med 2002;1:1-16
30. Fujinaga Y. Transport of bacterial toxins into target cells: pathways followed by cholera toxin and botulinum progenitor toxin. J Biochem 2006;140:155-160 (Pubitemid 44618900)
31. Zhang R-G, Scott DL, Westbrook ML, et al. The three-dimensional crystal structure of cholera toxin. J Mol Biol 1995;251:563-573
32. Fan E, O'Neal CJ, Mitchell DD, et al. Structural biology and structure-based inhibitor design of cholera toxin and heat-labile enterotoxin. Int J Med Microbiol 2004;294:217-223 (Pubitemid 39381973)
33. O'Neal CJ, Amaya EI, Jobling MG, et al. Crystal structures of an intrinsically active cholera toxin mutant yield insight into the toxin activation mechanism. Biochemistry 2004;43:3772-3782
34. van den Akker F, Merritt EA, Pizza M, et al. The Arg7Lys mutant of heat-labile enterotoxin exhibits great flexibility of active site loop 47-56 of the A subunit. Biochemistry 1995;34:10996-11004
35. Merritt EA, Kuhn P, Sarfaty S, et al. The 1.25 Å resolution refinement of the cholera toxin B-pentamer: evidence of peptide backbone strain at the receptor-binding site. J Mol Biol 1998;282:1043-1059 (Pubitemid 28468202)
36. Zenser TV. Inhibition of cholera toxin-stimulated intestinal epithelial cell adenylate cyclase by adenosine analogs. Proc Soc Exp Biol Med 1976;152:126-129
37. Velter IA, Politi M, Podlipnik C, Nicotra F. Natural and synthetic cholera toxin antagonists. Mini Rev Med Chem 2007;7:159-170 (Pubitemid 46592179)
38. Saito T, Miyake M, Toba M, et al. Inhibition by apple polyphenols of ADP-ribosyltransferase activity of cholera toxin and toxin-induced fluid accumulation in mice. Microbiol Immunol 2002;46:249-255 (Pubitemid 34456677)
39. Toda M, Okubo S, Ikigai H, et al. The protective activity of tea catechins against experimental infection by Vibrio cholerae O1. Microbiol Immunol 1992;36:999-1001
40. Zhou GC, Parikh SL, Tyler PC, et al. Inhibitors of ADP-ribosylating bacterial toxins based on oxacarbenium ion character at their transition states. J Am Chem Soc 2004;126:5690-5698
41. Zhang G. Design, synthesis, and evaluation of bisubstrate analog inhibitors of cholera toxin. Bioorg Med Chem Lett 2008;18:3724-3727 (Pubitemid 351794514)
42. Podlipnik C. Docking of selected natural polyphenols to ARF activated A1 subunit of Cholera toxin. Acta Chim Slov 2009;56:156-165
43. Locht C, Antoine R. A proposed mechanism of ADP-ribosylation catalyzed by the pertussis toxin S1 subunit. Biochimie 1995;77:333-340
44. Lobet Y, Cluff CW, Cieplak WJ. Effect of site-directed mutagenic alterations on ADP-ribosyltransferase activity of the A subunit of Escherichia coli heat-labile enterotoxin. Infect Immun 1991;59:2870-2879
45. Cieplak WJ, Mead DJ, Messer RJ, Grant CC. Site-directed mutagenic alteration of potential active-site residues of the A subunit of Escherichia coli heat-labile enterotoxin. Evidence for a catalytic role for glutamic acid 112. J Biol Chem 1995;270:30545-30550 (Pubitemid 26005113)
46. Kaslow HR, Platter B, Takada T, et al. Bacterial protein toxins ASM Press: New York, 1992
47. Jobling MG, Holmes RK. Biological and biochemical characterization of variant A subunits of cholera toxin constructed by site-directed mutagenesis. J Bacteriol 2001;183:4024-4032
48. Oppenheimer NJ. Structural determination and stereospecificity of the choleragen-catalyzed reaction of NAD+ with guanidines. J Biol Chem 1978;253:4907-4910
49. Soman G, Narayanan J, Martin BL, Graves DJ. Use of substituted (benzylidineamino)guanidines in the study of guanidino group specific ADP-ribosyltransferase. Biochemistry 1986;25:4113-4119 (Pubitemid 16045637)
50. Scheuring J, Schramm VL. Pertussis toxin: transition state analysis for ADP-ribosylation of G-protein peptide alphai3C20. Biochemistry 1997;36:8215-8223 (Pubitemid 27297530)
51. Scheuring J, Schramm VL. Kinetic isotope effect characterization of the transition state for oxidized nicotinamide adenine dinucleotide hydrolysis by pertussis toxin. Biochemistry 1997;36:4526-4534 (Pubitemid 27180300)
52. Rising KA, Schramm VL. Transition state analysis of NAD+ hydrolysis by the cholera toxin catalytic subunit. J Am Chem Soc 1997;119:27-37 (Pubitemid 27064479)
53. Li J, Zhang G, Zhang Z, Fan E. TFA-sensitive arylsulfonylthiourea- assisted synthesis of N,N′-substituted guanidines. J Org Chem 2003;68:1611-1614 (Pubitemid 36232538)
54. Lewandowicz A, Tyler PC, Evans GB, et al. Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase. J Biol Chem 2003;278:31465-31468 (Pubitemid 37048321)
55. Lee YC, Lee RT. Carbohydrate-protein Interactions: basis of glycobiology. Acc Chem Res 1995;28:321-327
56. Mammen M, Choi S-K, Whitesides GM. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed 1998;37:2754-2794 (Pubitemid 29008561)
57. Kitov PI, Sadowska JM, Mulvey G, et al. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 2000;403:669-672 (Pubitemid 30104009)
58. Kitova EN, Kitov PI, Bundle DR, Klassen JS. The observation of multivalent complexes of Shiga-like toxin with globotriaoside and the determination of their stoichiometry by nanoelectrospray Fourier-transform ion cyclotron resonance mass spectrometry. Glycobiology 2001;11:605-611
59. Ho JGS, Kitov PI, Paszkiewicz E, et al. Ligand-assisted aggregation of proteins: dimmerization of serum amyloid P component by bivalent ligands. J Biol Chem 2005;280:31999-32008 (Pubitemid 41291951)
60. Solomon D, Kitov PI, Paszkiewicz E, et al. Heterobifunctional multivalent inhibitor-adaptor mediates specific aggregation between Shiga toxin and a pentraxin. Org Lett 2005;7:4369-4372 (Pubitemid 41436649)
61. Kitov PI, Mulvey GL, Griener TP, et al. In vivo supramolecular templating enhances the activity of multivalent ligands: a potential therapeutic against the Escherichia coli O157 AB5 toxins. Proc Natl Acad Sci USA 2008;105:16837-16842
62. Liu J, Zhang Z, Tan X, et al. Protein heterodimerization through ligand-bridged multivalent pre-organization: enhancing ligand binding toward both protein targets. J Am Chem Soc 2005;127:2044-2045 (Pubitemid 40270498)
63. Zhang Z, Merritt EA, Ahn M, et al. Solution and crystallographic studies of branched multivalent ligands that inhibit the receptor-binding of cholera toxin. J Am Chem Soc 2002;124:12991-12998 (Pubitemid 35247110)
64. Merritt EA, Zhang Z, Pickens JC, et al. Characterization and crystal structure of a high-affinity pentavalent receptor-binding inhibitor for cholera toxin and E. coli heat-labile enterotoxin. J Am Chem Soc 2002;124:8818-8824 (Pubitemid 34809625)
65. Fan E, Zhang Z, Minke WE, et al. High-affinity pentavalent ligands of Escherichia coli heat-labile enterotoxin by modular structure-based design. J Am Chem Soc 2000;122:2663-2664 (Pubitemid 30211987)
66. Liu J, Begley D, Mitchell DD, et al. Multivalent drug design and inhibition of cholera toxin by specific and transient protein-ligand Interactions. Chem Biol Drug Des 2008;71:408-419
67. Polizzotti BD, Maheshwari R, Vinkenborg J, Kiick KL. Effects of saccharide spacing and chain extension on toxin inhibition by glycopolypeptides of well-defined architecture. Macromolecules 2007;40:7103-7110 (Pubitemid 47583054)
68. Zhang Z, Pickens JC, Hol WGJ, Fan E. Solution- and solid-phase syntheses of guanidine-bridged, water-soluble linkers for multivalent ligand design. Org Lett 2004;6:1377-1380 (Pubitemid 38626308)
69. Merritt EA, Sixma TK, Kalk KH, et al. Galactose-binding site in Escherichia coli heat-labile enterotoxin (LT) and cholera toxin (CT). Mol Microbiol 1994;13:745-753 (Pubitemid 24266209)
70. Mitchell DD, Pickens JC, Korotkov K, et al. 3,5-Substituted phenyl galactosides as leads in designing effective cholera toxin antagonists: synthesis and crystallographic studies. Bioorg Med Chem 2004;12:907-920
71. Zhang Z, Liu J, Verlinde CLMJ, et al. Large cyclic peptides as cores of multivalent ligands: application to inhibitors of receptor binding by cholera toxin. J Org Chem 2004;69:7737-7740 (Pubitemid 39403364)
72. Vrasidas I, Mol NJD, Liskamp RMJ, Pieters RJ. Synthesis of lactose dendrimers and multivalency effects in binding to the cholera toxin B subunit. Eur J Org Chem 2001:4685-4692 (Pubitemid 33726866)
73. Arosio D, Vrasidas I, Valentini P, et al. Synthesis and cholera toxin binding properties of multivalent GM1 mimics. Org Biomol Chem 2004;2:2113-2124
74. Branderhorst HM, Liskamp RMJ, Visser GM, Pieters RJ. Strong inhibition of cholera toxin binding by galactose dendrimers. Chem Commun 2007:5043-5045 (Pubitemid 350197647)
75. Pukin AV, Branderhorst HM, Sisu C, et al. Strong inhibition of cholera toxin by multivalent GM1 derivatives. ChemBioChem 2007;8:1500-1503 (Pubitemid 47436905)
76. Sisu C, Baron AJ, Branderhorst HM, et al. The influence of ligand valency on aggregation mechanisms for inhibiting bacterial toxins. ChemBioChem 2009;10:329-337
77. Bernardi A, Arosio D, Sonnino S. Mimicking gangliosides by design: mimics of GM1 headgroup. Neurochem Res 2002;27:539-545
78. Bernardi A, Checchia A, Brocca P, et al. Sugar mimics: an artificial receptor for cholera toxin. J Am Chem Soc 1999;121:2032-2036 (Pubitemid 129540933)
79. Bernardi A, Arosio D, Manzoni L, et al. Mimics of ganglioside GM1 as cholera toxin ligands: replacement of the GalNAc residue. Org Biomol Chem 2003;1:785-792
80. Arosio D, Fontanella M, Baldini L, et al. A synthetic divalent cholera toxin glycocalix[4]arene ligand having higher affinity than natural GM1 oligosaccharide. J Am Chem Soc 2005;127:3660-3661
81. Sinclair HR, Smejkal CW, Glister C, et al. Sialyloligosaccharides inhibit cholera toxin binding to the GM1 receptor. Carbohydr Res 2008;343:2589-2594
82. Liu S, Kiick KL. Architecture effects on the binding of cholera toxin by helical glycopolypeptides. Macromolecules 2008;41:764-772 (Pubitemid 351294489)
83. Rai P, Padala C, Poon V, et al. Statistical pattern matching facilitates the design of polyvalent inhibitors of anthrax and cholera toxins. Nat Biotechnol 2006;24:582-586
84. Polyzos A, Alderton MR, Dawson RM, Hartley PG. Biofunctionalized surfactant mesophases as polyvalent inhibitors of cholera toxin. Bioconjug Chem 2007;18:1442-1449 (Pubitemid 47464051)
85. Shi J, Yang T, Kataoka S, et al. GM1 clustering inhibits cholera toxin binding in supported phospholipid membranes. J Am Chem Soc 2007;129:5954-5961 (Pubitemid 46748502)
86. Halgren TA, Murphy RB, Friesner RA, et al. Glide: a new approach for rapid, accurate docking and scoring, Part 2: Enrichment factors in database screening. J Med Chem 2004;47:1750-1759 (Pubitemid 38380918)
87. Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. I. Method and assessment of docking accuracy. J Med Chem 2004;47:1739-1749
88. Morris GM, Goodsell DS, Huey R, Olson AJ. Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J Comput Aided Mol Des 1996;10:293-304 (Pubitemid 126712824)
89. Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998;19:1639-1662
90. Zhang G. Design, synthesis and evaluation of cholera toxin inhibitors. Doctoral Thesis, University of Washington, 2006
91. Srebnik S, Shakhnovich EI, Chakraborty AK. Adsorption/freezing transition for random heteropolymers near disordered 2-D manifolds due to pattern matching. Phys Rev Lett 1996;77:3157-3160 (Pubitemid 126624230)
92. Golumbfskie AJ, Pande VS, Chakraborty AK. Simulation of biomimetic recognition between polymers and surfaces. Proc Natl Acad Sci USA 1999;96:11707-11712
93. Podlipnik C, Velter I, Ferla BL, et al. First round of a focused library of cholera toxin inhibitors. Carbohydr Res 2007;342:1651-1660 (Pubitemid 47058072)
94. Podlipnik C, Bernardi A. Design of a focused virtual library to explore cholera toxin B-site. Acta Chim Slov 2007;54:425-436
95. Chen D, Menche G, Power TD, et al. Accounting for ligand-bound metal ions in docking small molecules on adenylyl cyclase toxins. Proteins Struct Funct Bioinform 2007;67:593-605 (Pubitemid 46625576)
96. Minke WE, Diller DJ, Hol WG, Verlinde CL. The role of waters in docking strategies with incremental flexibility for carbohydrate derivatives: heat-labile enterotoxin, a multivalent test case. J Med Chem 1999;42:1778-1788
97. NCI Diversity Dataset. Available from: http://autodock.scripps.edu/ resources/databases
98. Sharmilaa DJS, Veluraja K. Conformations of higher gangliosides and their binding with cholera toxin - investigation by molecular modeling, molecular mechanics, and molecular dynamics. J Biomol Struct Dyn 2006;23:641-656 (Pubitemid 43726243)
99. Kolb HC, Finn MG, Sharpless KB. Click chemistry: diverse chemical function from a few good reactions. Angew. Chem Int Ed 2001;40:2004-2021
100. Rosenzweig BA, Ross NT, Tagore DM, et al. Multivalent protein binding and precipitation by self-assembling molecules on a DNA pentaplex scaffold. J Am Chem Soc 2009;131:5020-5021
101. Chung WY, Carter R, Hardy T, et al. Inhibition of Escherichia coli heat-labile enterotoxin B subunit pentamer (EtxB5) assembly in vitro using monoclonal antibodies. J Biol Chem 2006;281:39465-39470 (Pubitemid 46041906)
102. Ni J, Singh S, Wang L-X. Improved preparation of perallylated cyclodextrins: facile synthesis of cyclodextrin-based polycationic and polyanionic compounds. Carbohydr Res 2002;337:217-220 (Pubitemid 34158990)
103. Shin SBY, Yoo B, Todaro LJ, Kirshenbaum K. Cyclic peptoids. J Am Chem Soc 2007;129:3218-3225
104. Bowman M-C, Ballard TE, Ackerson CJ, et al. Inhibition of HIV fusion with multivalent gold nanoparticles. J Am Chem Soc 2008;130:6896-6897
105. Seifert MHJ. Targeted scoring functions for virtual screening. Drug Discov Today 2009;14:562-569
106. Charifson PS, Corkery JJ, Murcko MA, Walters WP. Consensus scoring: a method for obtaining improved hit-rates from docking databases of three-dimensional structures into proteins. J Med Chem 1999;42:5100-5109
107. Wang R, Wang S. How does consensus scoring work for virtual library screening? An idealized computer experiment. J Chem Inf Comput Sci 2001;41:1422-1426 (Pubitemid 33663908)
108. Bissantz C, Folkers G, Rognan D. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. J Med Chem 2000;43:4759-4767
109. Teramoto R, Fukunishi H. Supervised consensus scoring for docking and virtual screening. J Chem Inf Model 2007;47:526-534 (Pubitemid 46615954)
110. Taroni C, Jones S, Thornton JM. Analysis and prediction of carbohydrate binding sites. Protein Eng 2000;13:89-98 (Pubitemid 30151039)
111. Kerzmann A. Fuhrmann J, Kohlbacher O, Neumann D. BALLDock/SLICK: a new method for protein-carbohydrate docking. J Chem Inf Model 2008;48:1616-1625